Physician profile
Alla Stepanova
NPI 1851893986
$4,880.08
in general payments reported to CMS, 2019-2025
37 companies · $197 in 2025
The $197 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,002 · 2022: $1,344 · 2023: $987 · 2024: $351 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,534.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $568.18 | 2021-2025 | |
| Novo Nordisk INC | $512.93 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $478.75 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $388.50 | 2021-2024 | Breztri, Farxiga |
| Gilead Sciences, INC. | $284.38 | 2021-2022 | |
| Amgen INC. | $245.85 | 2021-2025 | Otezla, Repatha, Otezla |
| Amarin Pharma, INC. | $216.94 | 2021-2022 | |
| Esperion Therapeutics, INC. | $167.78 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $160.66 | 2021 | |
| Novartis Pharmaceuticals Corporation | $158.58 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $153.64 | 2022-2023 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.59 | 2021-2023 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $137.05 | 2021-2022 | |
| Almatica Pharma LLC | $134.66 | 2021-2023 | Gralise, Loreev Xr, Sertraline Hcl |
| Bayer Healthcare Pharmaceuticals INC. | $133.72 | 2022-2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $124.99 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.70 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $72.02 | 2021-2022 | |
| Abbott Laboratories | $69.35 | 2021-2023 | Freestyle Libre 3 |
| Mannkind Corporation | $66.30 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $59.78 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $57.39 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $48.42 | 2021 | |
| Exact Sciences Corporation | $48.15 | 2023 | Cologuard Collection Kit |
| Pfizer INC. | $47.97 | 2021-2023 | |
| Antares Pharma, INC. | $41.35 | 2021-2023 | Nocdurna, Tlando, Xyosted |
| Corcept Therapeutics | $37.04 | 2022 | |
| Edwards Lifesciences Corporation | $30.50 | 2023 | |
| Dexcom, INC. | $24.20 | 2025 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $23.65 | 2021 | |
| Impel Pharmaceuticals INC. | $21.82 | 2023 | Trudhesa |
| Acerus Pharmaceuticals Corporation | $19.90 | 2022 | |
| Halozyme INC | $19.90 | 2023 | |
| Vivus LLC | $19.07 | 2021 | |
| Tonix Medicines, INC. | $17.82 | 2025 | Tonmya |
| Viiv Healthcare Company | $17.05 | 2023 | Apretude |
| Eisai INC. | $13.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alla Stepanova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.